Senseonics (NYSE:SENS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

Senseonics Stock Down 3.6 %

Shares of Senseonics stock opened at $0.37 on Tuesday. The company has a quick ratio of 3.70, a current ratio of 3.96 and a debt-to-equity ratio of 1.79. Senseonics has a twelve month low of $0.37 and a twelve month high of $1.05. The company has a market cap of $194.41 million, a price-to-earnings ratio of -2.62 and a beta of 0.82. The company’s 50 day moving average is $0.44 and its 200 day moving average is $0.53.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $5.05 million for the quarter, compared to the consensus estimate of $4.76 million. Senseonics had a negative return on equity of 202.32% and a negative net margin of 346.38%. Research analysts anticipate that Senseonics will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SENS. RPO LLC purchased a new position in shares of Senseonics in the fourth quarter valued at about $37,000. State Board of Administration of Florida Retirement System purchased a new position in Senseonics in the 1st quarter worth approximately $91,000. Virtu Financial LLC bought a new position in Senseonics in the 1st quarter worth approximately $162,000. Price T Rowe Associates Inc. MD grew its holdings in Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after buying an additional 211,128 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.